Skip to main content
. 2021 Sep 29;16(9):e0257474. doi: 10.1371/journal.pone.0257474

Fig 1. Efficacy studies.

Fig 1

Flow chart depicting the order in which training phases and experimental design were conducted. The number of days after phases 1, 2, and 3 indicate the time employed training the dogs before running efficacy experiments; in the case of phase 4, the time without training before starting the effectiveness experiments. COVID-19 prevalence was set up as desired for in vitro experiments, introducing a more difficult scenario by minimizing prevalence during phase 2 (in vitro diagnosis). Prevalence during phases 3 and 4 (in vivo screening) was spontaneous, given by the pandemic epidemiology of the different human groups participating in the study.